Trial Profile
A Randomized Placebo-controlled Single Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- 17 Oct 2023 Status changed from active, no longer recruiting to completed.
- 16 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 16 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.